Anthonet Koen - Concepedia

Concepedia

Author

Anthonet Koen

University of the Witwatersrand

Also Known As

A Koen, A. Koen, Anthonet Koen, Anthonet L Koen, Anthonet L. Koen, Anthonet Lombard Koen, Mehreen Jalilzadeh Khoie

57

Publications

9.8K

Citations

25

H-Index

30

Concepts

All Affiliations

University of the Witwatersrand South African Medical Research Council National Research Foundation Respiratory and Meningeal Pathogens Research Unit University of Cape Town

AK

About

Anthonet Koen is an author at University of the Witwatersrand specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	485
2	Immunology	6	6	324
3	Public Health	3	3	325
4	Epidemiology	3	3	325
5	Newborn Medicine	1	1	58

Anthonet Koen

×

32

Publications

9.8K

Citations

25

H-Index

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, New England Journal of Medicine	2021	1.3K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, New England Journal of Medicine	2021	652
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial Shabir A. Madhi, Clare Cutland, Lisa Jose, The Lancet Infectious Diseases VaccinationVaccine SafetyMaternal ImmunizationRandomised Phase 1B/2Vaccine Testing	2016	161
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial Shabir A. Madhi, Anthonet Koen, Alane Izu, The Lancet HIV	2021	159
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial Michelle J. Groome, Anthonet Koen, Alan Fix, The Lancet Infectious Diseases	2017	138
Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial Robert S. Heyderman, Shabir A. Madhi, Neil French, The Lancet Infectious Diseases	2016	125
Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, ImmunodeficienciesImmunologyCovid-19 EpidemiologyLive VirusCovid-19	2021	122
Trivalent Inactivated Influenza Vaccine in African Adults Infected With Human Immunodeficient Virus: Double Blind, Randomized Clinical Trial of Efficacy, Immunogenicity, and Safety Shabir A. Madhi, Mhairi Maskew, Anthonet Koen, Clinical Infectious Diseases	2010	94

Page 1